Program Overview
Technology-assisted buprenorphine (TAB) treatment is a novel program promoting illicit opioid absence and buprenorphine-naloxone adherence. TAB has four primary components. The first is bimonthly visits where patients provide a urine specimen, receive buprenorphine-naloxone sublingual tablets under supervision, and are supplied with the rest of the patient’s tablets (until the next visit) to be dispensed at home via a portable device set to allow access a dose during a specified time window. The second component is daily monitoring via an interactive voice response (IVR) telephone system. The IVR calls assess opioid use, craving, withdrawal, and other drug and alcohol use and connects patients to appropriate resources or staff depending on the answers to the questions. Patients are also randomly called back to provide urine samples and remaining doses twice a month via the IVR system. In addition, TAB includes iPad-administered HIV and hepatitis C virus (HCV) education providing immediate correct feedback.
Last Updated: 08/29/2024
Delivery
IVR
iPad
Target Substances
Opioids
Target Outcomes
Illicit opioid abstinence
HIV and HCV knowledge
Age
Young adult: 18 – 30 years
Adult: 30+ years
Gender
Male
Female
Race
American Indian or Alaska Native
Black or African American
Multiracial
White
Other
Ethnicity
Hispanic
Setting
Rural
Urban
Geographic Location
United States
Language
English
Index Study Publication Date
September 27, 2023